Tiger Brokers

  • Quotes
  • Products
    • Cash Boost Account
    • US Stocks
    • US Fractional Shares
    • HK Stocks
    • China A-shares
    • Options
    • Futures
    • US Treasury
    • Auto-invest
    • Fixed Coupon Notes
    • Tiger BOSS Debit Card
    • Fund Mall
    • Tiger Vault
    • Tiger Open Platform
    • Wealth
  • Pricing
    • Prime
      • Stocks & ETFs
      • Options, Warrants & CBBCs
      • Futures
      • Bonds
      • Fund Mall
    • Cash Boost
      • Stocks & ETFs
    • Financing Interest Rates
  • Promotions
  • Help
    • Account Operations
      • How to Open an Account?
      • Account Opening Documents
      • Account Types Available
    • Transfer & Pay
      • Account Funding
      • DDA Fast Deposit
      • Funds Withdrawal
      • Shares Transfer-in
      • Shares Transfer-out
      • Currency Conversion
    • Products & Trading
      • Products Available
      • Order Types
      • Trading Rules
      • Declaration
    • Margin Trading & Short Selling
      • Margin & Leverage
      • Risk Management
      • Short Selling Risk
    • Fund Mall
      • Open a fund account and transaction
    • Cash Boost Account
      • Cash Boost Account FAQ
      • How to Open Cash Boost Account
      • How to Contra Trade using Cash Boost Account
      • How to link your CDP Securities Account
    • Tiger Boss Debit Card
      • Frequently Asked Questions
      • Fees of the Debit card
      • How to Top-up
      • How to use my Debit card
    • Tiger Vault
      • Features of Tiger Vault
      • Transaction Fees
    • Statement
      • Statement
      • Dividends
  • Learn
  • TigerAI
  • Institution
    • Wealth and asset manager
    • Proprietary trading institutions
    • Introducing brokers
    • Third-party service provider
  • Careers
    • L.E.A.P Programme
    • Investment Representative
    • Careers Portal
  • LOGIN
  • SIGN UP
HK StockDetailed Quotes
Provided by Tiger Fintech (Singapore) Pte. Ltd.

ASCLETIS-B

8.610
-0.490-5.38%
Volume:4.79M
Turnover:41.78M
Market Cap:8.30B
PE:-26.18
High:9.300
Open:9.110
Low:8.560
Close:9.100
Loading ...
OverviewCompanyNewsFilings

Concept

Post-Pandemic Stocks+1.57%
Nonprofit Pharmaceutical Companies-2.33%

Capital Flow

 
Inflow:
 
Outflow:
 
 
 
 
 
 
 
 
 
 
 
 
 
 

News

Ascletis Announces First Participants Dosed in U.S. Phase I Clinical Study of Asc50, a Potential Best-in-Class Oral Small Molecule Il-17 Inhibitor for the Treatment of Psoriasis

THOMSON REUTERS
·
18 Jun

Ascletis Pharma Inc. Announces First Participants Dosed in U.S. Phase I Clinical Trial of Potential Best-in-Class Psoriasis Treatment ASC50

Reuters
·
18 Jun

HK Movers | HK's Biotech Shares Soar. JOINN Soars 8%; Fudan-Zhangjiang up 6%; HeartCare up 2%

Tiger Newspress
·
17 Jun

HK Movers | Biotech Stocks Jump. Canbridge Soars 40%; Ascletis Jumps 17%; TYK Medicines Gains 7%; HBM Holdings, Abbisko Up More Than 6%

Tiger Newspress
·
16 Jun

Analyst Rate

Buy
Buy
80.00%
Hold
20.00%
Sell
0.00%

Corporate Actions

Financial Report Announcement
Mar 26, 2025 Pre-Market
Financial Report Announcement
Aug 30, 2024
Financial Report Announcement
Mar 25, 2024
Financial Report Announcement
Aug 21, 2023
Financial Report Announcement
Mar 20, 2023

Dividend History

no data

No relevant data is available

Valuation Analysis

-25.15
Current
-14.86
Sector Average
18.36%
Historical Percentile
P/E[TTM]
+1 STD
Average
-1 STD
Current
-25.15
Maximum
-3.06
+1 STD
-6.66
Minimum
-34.76
-1 STD
-23.06
Average
-14.86

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10
     
     
     
     
Company Name:
Tiger Fintech (Singapore) Pte. Ltd.
Email Address:
uservice@ttm.financial
User Agreement|Privacy Policy

Copyright © Tiger Fintech (Singapore) Pte. Ltd.

Product offerings in different jurisdictions may vary.

Information contained on this website is general in nature and does not take into account of your investment objectives, financial situation and specific needs. It should not be regarded as an offer to sell, asolicitation to buy, a recommendation or endorsement for any financial product, nor does it constitute an investment forecast, investment return commitments, investment suggestions or other practical operating opinions. Information contained on this website is for reference only and past performance should not be construed as future performance. Investment involves risks. Before you make an investment decision, you should carefully judge and screen whether the information contained on this website is appropriate for your needs, goals and circumstances.

We strive but cannot guarantee the accuracy, completeness, reliability and timeliness of all information on this website, and we are not responsible for any losses caused by the use of or reliance on relevant information.

The products and services offered on the website are subject to applicable laws, regulations and relevant agreements. Please carefully read and agree to the agreements before using our products and services.